CKD-anemia Flashcards
List the EPA drugs
epoeitin alfa: eprex
epoeitin beta: recormon
darbepoeitin
micera
clinical presentation of anemia
- asymptomatic at first (lungs and heart compensate)
- SOB, lethargy, poor appetite conjunctival pallor
decreased O2 delivery to organs
what Hgb levels are needed for anemia treatment
<10 g/dL
dont give to ppl with > 11g/dL if not greater risk of CVS complications
goal Hgb count is 10-11.5 g/dL
dont exceed >13g/dL
goal levels of TSAT and serum ferritin
TSAT: > 20%
serum ferritin: >200 for HD, >100 non HD
SE of ESA
- HTN (Not a contraindication unless uncontrolled)
- Vascular access thrombosis
- Seizures (?) ‒ Prior h/o of seizure is not a contraindication of ESA use
- Flu-like syndrome
- Reduced dialysis efficiency
- Pure red cell aplasia
but its generally well tolerated
whats pure red cell aplasia
- development of neutralizing antibodies to ESAs and endogenous EPO
- Resulting in absolute resistance to therapy requiring blood transfusions
- Need to discontinue therapy to prevent anaphylactic reactions - Associated with SC admin of epoetin alfa (Eprex) and suboptimal storage/transport conditions
only after ruling out hyporesponsiveness/resistance to ESA then check for PRCA
causes of hyporesponsiveness/resistance to ESA
- Iron deficiency (most common cause!)
- Hyperparathyroidism (direct bone marrow suppression)
- Inflammation/infection (impair delivery of Fe to bone marrow)
- Malignancies, chemotherapy, AIDS
- Malnutrition (substrate deficiencies); hypoalbuminemia
- blood loss, chronic bleeding, Al toxicity
MOA of ESA
stimulate differentiation of erythroid progenitor stem cells and induce release of reticulocytes from bone marrow
(initial) dosing of eprex
50-100 units/kg 3x/week IV
in singapore is IV only
(initial) dosing of recormon
40 units/kg 3x/week IV or SC
(initial) dose of darbepoetin alfa (aranesp)
0.45mcg/kg 1x per week IV or SC
PD: once every 2 weeks
longer half life can impreve pt compliance
(initial) dose of micera
0.6 mcg/kg q2weeks IV or SC
PEGylated epoetin –> increases stability –> increases half life
less frequent administration can improve half life
monitoring after administering ESA
when and monitor what
- measure Hgb every 2-4 weeks following initiation/dose change
- after stable monitoe every 3 months
what to do if allergy/resistance to ESA
- use hypoxia inducible factor propyl hydroxylase inhibitors (HIF - PHIs)
- stimulate EPO transcription in kidneys and liver
Not recommended for non-dialysis CKD due to lack of long term safety
dosage forms of iron spplementation
- PO (1st line)
- IV (in HD when PO is insufficient)
- Transfusion (last line)